CHM is an advisory committee not unlike what FDA has. If and when overwhelming evidence and support are in play the CHM meeting may not really be needed as just another rubber stamp. If there are significant questions or potential delays due to certain issues then a CHM meeting might be employed to make a recommendation based on their perspective. This is a normal course of action for many approvals because of safety and risk factors. With this treatment being called a placebo by the basher/bears even they profess there is no real safety risk factors to consider hence the POTENTIAL to jump past CHM. This is not a guarantee by any stretch of the imagination but… this is a well understood treatment from all the external and internal evidence compiled over more than 20 plus years in at least 5 jurisdictions including Israel, Germany, UK, Canada and USA with India having their own version of L similar but just confirming patent protection for Direct. Can longs hear NWBO now?; ). Best wishes.
Market Data 
Markets 
AI
